Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).

What Was Tested

Researchers studied Copper (Supplement) in the context of dementia, alzheimer's & cognitive decline in this randomized controlled trial publication.

Who Took Part

According to the abstract, 7540 men were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study.

Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the men nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen.

During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen.

In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment.

What Was Measured

The subject headings attached to it are Alzheimer Disease, Antioxidants, Dementia, Dietary Supplements, Longitudinal Studies, Outcome Assessment, Health Care and Selenium.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 7540 men in people with dementia, alzheimer's & cognitive decline.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (JAMA neurology), a journal based in United States.

More context: the Copper (Supplement) compound page, Dementia, Alzheimer's & cognitive decline research.